As of Jul 13, 2026, the VRTX stock has a PE ratio of 28.23. The calculation is based on the latest EPS of $17.01 and the stock price of $480.25 per share. The PE ratio currently is comparable to its last four-quarter average.
The mean historical PE ratio of Vertex Pharmaceuticals over the last ten years is 50.29. The current 28.23 price-to-earnings ratio is 44% less than the historical average. Analyzing the last ten years, VRTX's PE ratio reached its highest point in the Sep 2017 quarter at 190.05, with a price of $152.04 and an EPS of $0.8. The Dec 2018 quarter saw the lowest point at 20.11, with a price of $165.71 and an EPS of $8.24.
Maximum annual increase: 137.74% in 2019
Maximum annual decrease: -85.78% in 2018
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 29.32 | N/A | $453.36 | $15.46 |
| 2024 | N/A | N/A | $402.7 | -$2.08 |
| 2023 | 28.96 | 30.04% | $406.89 | $14.05 |
| 2022 | 22.27 | -7.82% | $288.78 | $12.97 |
| 2021 | 24.16 | 6.71% | $219.6 | $9.09 |
| 2020 | 22.64 | -52.65% | $236.34 | $10.44 |
| 2019 | 47.81 | 137.74% | $218.95 | $4.58 |
| 2018 | 20.11 | -85.78% | $165.71 | $8.24 |
| 2017 | 141.38 | N/A | $149.86 | $1.06 |
| 2016 | N/A | N/A | $73.67 | -$0.46 |
| 2015 | N/A | N/A | $125.83 | -$2.31 |
| 2014 | N/A | N/A | $118.8 | -$3.14 |
| 2013 | N/A | N/A | $74.3 | -$1.98 |
| 2012 | N/A | N/A | $41.9 | -$0.5 |
| 2011 | 237.21 | N/A | $33.21 | $0.14 |
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 26.25 | -10.47% | $446.54 | $17.01 |
| Dec 2025 | 29.32 | 7.12% | $453.36 | $15.46 |
| Sep 2025 | 27.37 | -13.19% | $391.64 | $14.31 |
| Jun 2025 | 31.53 | N/A | $445.2 | $14.12 |
| Mar 2025 | N/A | N/A | $484.82 | -$3.82 |
| Dec 2024 | N/A | N/A | $402.7 | -$2.08 |
| Sep 2024 | N/A | N/A | $465.08 | -$1.85 |
| Jun 2024 | N/A | N/A | $468.72 | -$1.89 |
| Mar 2024 | 26.83 | -7.35% | $418.01 | $15.58 |
| Dec 2023 | 28.96 | 12.16% | $406.89 | $14.05 |
| Sep 2023 | 25.82 | -3.94% | $347.74 | $13.47 |
| Jun 2023 | 26.88 | 8.43% | $351.91 | $13.09 |
| Mar 2023 | 24.79 | 11.32% | $315.07 | $12.71 |
| Dec 2022 | 22.27 | -1.55% | $288.78 | $12.97 |
| Sep 2022 | 22.62 | 0.09% | $289.54 | $12.8 |
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
VRTX's current PE ratio is higher than the 3 and 5-year averages, but it is under its 10-year average.
Vertex Pharmaceuticals's price to earnings (P/E) of 28.23 is higher than the Healthcare sector, the industry and its peers average. Looking at the Healthcare sector average of 25.82, Vertex Pharmaceuticals's price to earnings (P/E) is 9% higher.
When compared to its peers JNJ and ABBV, VRTX's PE ratio is lower, but it is higher than GILD's and BMY's. Vertex Pharmaceuticals is currently trading at a higher PE ratio (28.23) than its peers average of 24.65.
| Stock name | PE ratio | Market cap |
|---|---|---|
| BMY Bristol Myers Squibb Co | 16.62 | $121.18B |
| GILD Gilead Sciences Inc | 17.71 | $163.14B |
| VRTX Vertex Pharmaceuticals Inc | 28.23 | $121.89B |
| JNJ Johnson & Johnson | 29.53 | $620.51B |
| MRK Merck & Co Inc | 34.74 | $306.33B |
| ABBV AbbVie Inc | 122.17 | $438.16B |
| ENTA Enanta Pharmaceuticals Inc | N/A | $396.63M |
The price to earnings ratio for VRTX stock is 28.23 as of Jul 13, 2026.
Over the last 3 years, the average PE ratio for VRTX stock is 28.01.
Over the last 5 years, the average PE ratio for VRTX stock is 25.88.
The highest quarterly PE ratio in the last ten years has been 190.05 and it was in the Sep 2017 quarter.
VRTX's current price to earnings ratio is 44% below its 10-year historical average.
The P/E ratio is calculated by taking the latest stock price and dividing it by the earnings per share(EPS) for the last 12 months. As of today (Jul 13, 2026), Vertex Pharmaceuticals's share price is $480.25. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $17.01. Therefore, Vertex Pharmaceuticals's price to earnings ratio for today is 28.23. PE RATIO(28.23) = STOCK PRICE($480.25) / TTM EPS($17.01)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.